SOS: Solar Oxygen Study

Sponsor
University of Alberta (Other)
Overall Status
Completed
CT.gov ID
NCT03851783
Collaborator
Global Health Uganda LTD (Other)
2,405
20
2
29.7
120.3
4.1

Study Details

Study Description

Brief Summary

Globally, approximately 7.7 million children per year die before the age of 5 years. Infectious diseases account for a large proportion of these deaths, with pneumonia being the leading cause of mortality (2.1 million deaths/year). Most deaths occur in resource-poor settings in Asia and Africa. Oxygen (O2) therapy is essential to support life in these patients. Large gaps remain in the case management of children presenting to African hospitals with respiratory distress, including essential supportive therapies such as supplemental oxygen. In resource-constrained settings, oxygen delivery systems can lead to measurable improvements in survival from childhood pneumonia. A multihospital effectiveness study in Papua New Guinea demonstrated a reduction in mortality from childhood pneumonia from 5.0% to 3.2% (35% reduction in mortality) after implementation of enhanced oxygen delivery system. The investigators propose to investigate a novel strategy for oxygen delivery that could be implemented in remote locations with minimal access to an electrical power supply: solar-powered oxygen (SPO2).

Condition or Disease Intervention/Treatment Phase
  • Device: Solar-powered oxygen
N/A

Detailed Description

Clinical features of pneumonia in children include fever, respiratory distress, and hypoxemia. Respiratory distress is a useful clinical summary description with good inter-observer consistency among experienced medical practitioners. The following clinical signs may indicate increased work of breathing: sustained nasal flaring; indrawing (recession) of the bony structures of the chest wall (subcostal, intercostal, supraclavicular) on inspiration; tracheal tug; and deep breathing (acidotic or Kussmaul breathing). Respiratory distress is a sign that one or more serious pathological processes are at play: metabolic acidosis, fluid overload, acute lung injury, and/or co-morbid pneumonitis. Respiratory distress, together with alteration of consciousness, is a strong predictor of mortality in children with severe febrile illness in sub-Saharan Africa. The grim prognostic significance of respiratory distress applies to several disease states, irrespective of microbial etiology, including malaria as well as non-malaria febrile illness.

Arterial hypoxemia in pneumonia results from several mechanisms: pulmonary arterial blood flow to consolidated lung resulting in an intrapulmonary shunt, intrapulmonary oxygen consumption, and ventilation-perfusion mismatch. Hypoxemia is a risk factor for mortality in pediatric pneumonia, and was associated with a 5-fold increased risk of death in studies from Kenya and Gambia. In one report from Nepal, the prevalence of hypoxemia (SpO2 < 90%) in 150 children with pneumonia was 39% overall, with increasing rates of hypoxemia across strata of pneumonia severity (100% of very severe, 80% of severe and 17% of pneumonia patients). General features of respiratory distress were associated with hypoxemia in this study, including chest indrawing, lethargy, grunting, nasal flaring, cyanosis, inability to breastfeed or drink.

Oxygen is a lifesaving therapy for children with pneumonia and hypoxemia; however, challenges remain in oxygen delivery globally. Two main systems of oxygen delivery have been implemented and evaluated in resource-constrained settings, oxygen cylinders and oxygen concentrators. Oxygen cylinders are ready to use, simple to operate and do not require any electricity. However, cylinders are very costly and distribution and use is challenging. Oxygen concentrators have proven to be an effective means of delivering oxygen and are significantly less expensive that cylinders. However, oxygen concentrators require continuous and reliable electricity to operate which is not readily available in many regions, particularly in resource-limited settings where the majority of pneumonia deaths occur. In order to meet the demand for oxygen therapy in resource-limited settings, the investigators developed a novel strategy for oxygen delivery: solar-powered oxygen (SPO2). This system uses free inputs (sun and air) and could be implemented in remote locations with minimal access to an electrical power supply. Our group is the first to conduct rigorous scientific trials of SPO2.

To date, the investigators have accumulated substantial clinical experience with SPO2, having treated >150 hypoxemic children, over several years, at two Ugandan hospitals. Compared to other oxygen delivery methods, SPO2 is superior. SPO2 is more reliable than oxygen concentrators connected to grid electricity, because it is not affected by frequent power outages. SPO2 utilizes a renewable, sustainable and freely available source of energy. SPO2 is more reliable than compressed oxygen cylinders, which are frequently out of stock in the public hospital system. SPO2 is more user-friendly and safer for nurses than cylinders, which require physical strength to change regulators on high-pressure cylinders. SPO2 is less wasteful than cylinders, which tend to leak through ill-fitting regulators under real-world conditions.

The study is a multi-centre prospective evaluation of SPO2. The investigators will use a stepped-wedge cluster-randomized design to allow for robust scientific conclusions about the efficacy of SPO2. Importantly, demonstration of a mortality benefit of SPO2 will provide strong supportive evidence and could catalyse the widespread implementation of SPO2 in resource-limited settings across Africa and Asia.

Study Design

Study Type:
Interventional
Actual Enrollment :
2405 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Stepped-wedge cluster randomized controlled trial.Stepped-wedge cluster randomized controlled trial.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Solar Powered Oxygen Delivery on Childhood Mortality in Uganda: A Cluster-Randomized Trial
Actual Study Start Date :
Jul 1, 2019
Actual Primary Completion Date :
Dec 17, 2021
Actual Study Completion Date :
Dec 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Solar-powered oxygen

Solar panels used to drive an oxygen concentrator will deliver medical grade oxygen at a rate of 1-5L/min, for the treatment of children with hypoxemia.

Device: Solar-powered oxygen
Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.

No Intervention: Standard of care

Patients presenting with hypoxemia and pneumonia will be treated by standard of care prior to the implementation of solar-powered oxygen at a chosen site. This may include some allocation of oxygen via cylinders, but will likely be minimal or not available.

Outcome Measures

Primary Outcome Measures

  1. Mortality [48 hours]

    Mortality at 48 hours after admission

Secondary Outcome Measures

  1. In hospital mortality [Until end of hospitalization (usually 3 to 7 days)]

    Mortality during any point of hospital admission

  2. Length of hospital stay [Until end of hospitalization (usually 3 to 7 days)]

    Total length of hospital admission

  3. Oxygen saturation [Until end of hospitalization (usually 3 to 7 days)]

    Measured oxygen saturations before and after administration of oxygen, using standard procedures

  4. Oxygen delivery system failure [Until end of trial (24 months)]

    Number and duration of failures in any component of the oxygen delivery system, including solar panels, batteries, oxygen concentrator, and electrical components

  5. Total costs of implementing solar-powered oxygen delivery systems [Until end of trial (24 months)]

    Total costs of implementing solar-powered oxygen delivery systems at twenty sites, including installation, servicing and maintenance

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 5 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age under 5 years

  2. Hypoxemia (SpO2<92%) based on non-invasive pulse oximetry

  3. Hospital admission warranted based on clinician judgment

Exclusion Criteria:
  1. SpO2 ≥92%

  2. Outpatient management

  3. Denial of consent to participate in study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Adumi Health Centre IV Adumi Uganda
2 Apac District Hospital Apac Uganda
3 Atiak Health Centre IV Atiak Uganda
4 Bugobero Health Centre IV Bugobero Uganda
5 Bukedea Health Centre IV Bukedea Uganda
6 Bumanya Health Centre IV Bumanya Uganda
7 Bundibugyo Hospital Bundibugyo Uganda
8 Kagadi Hospital Kagadi Uganda
9 Kalisizo Hospital Kalisizo Uganda
10 Kamuli General Hospital Kamuli Uganda
11 Kayunga District Hospital Kayunga Uganda
12 Kidera Health Centre IV Kidera Uganda
13 Kitagata Hospital Kitagata Uganda
14 Kitgum General Hospital Kitgum Uganda
15 Kyenjojo General Hospital Kyenjojo Uganda
16 Lalogi Health Centre IV Lalogi Uganda
17 Lyantonde Hospital Lyantonde Uganda
18 Gombe Hospital Mpigi Uganda
19 Muyembe Health Centre IV Muyembe Uganda
20 Sembabule Health Centre IV Sembabule Uganda

Sponsors and Collaborators

  • University of Alberta
  • Global Health Uganda LTD

Investigators

  • Principal Investigator: Michael T Hawkes, MD, PhD, University of Alberta
  • Principal Investigator: Robert O Opoka, MBChB, MPH, Makerere University/Global Health Uganda

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Alberta
ClinicalTrials.gov Identifier:
NCT03851783
Other Study ID Numbers:
  • Pro00084784
First Posted:
Feb 22, 2019
Last Update Posted:
Feb 16, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Alberta
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2022